Investigation of the in-vitro uptake, intraphagocytic biological activity and effects on neutrophil superoxide generation of dirithromycin compared with erythromycin.
The cellular uptake by human neutrophils and the intraphagocytic biological activity of the new macrolide antimicrobial agent dirithromycin (0.01-2 mg/L) compared with erythromycin was investigated in vitro. Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila were used as the test intracellular microbial pathogens. After coincubation (45 min at 37 degrees C) of neutrophils with a fixed concentration of 2 mg/L of each antibiotic the respective intracellular/extracellular ratios for erythromycin and dirithromycin were 6.1 +/- 2.5 and 10.6 +/- 2 respectively (P < 0.005). Using a combination of techniques (colony counting, radiometry and fluorescence microscopy) both erythromycin and dirithromycin at concentrations of 0.01 and 0.5 mg/L and higher, respectively, were found to possess dose-related intraphagocytic bacteristatic activity for each of the test microbial pathogens. The effects of dirithromycin and erythromycin (1-20 mg/L) on neutrophil chemotaxis and generation of reactive oxidants by these cells were also investigated in vitro. Both antimicrobial agents caused a dose-related stimulation of neutrophil migration which was associated with inhibition of leucoattractant-activated generation of superoxide and activity of the myeloperoxidase/H2O2/halide system. However, superoxide generation by neutrophils activited with opsonized zymosan or phorbol myristate acetate was unaffected by the macrolides. These findings demonstrate that dirithromycin accumulates in human neutrophils, is biologically active intracellularly and modulates leucoattractant-activated superoxide generation and chemotaxis.
Jooné
G K
GK
Department of Immunology, University of Pretoria, Republic of South Africa.
Van Rensburg
C E
CE
Anderson
R
R
D000328:Adult; D000900:Anti-Bacterial Agents; D002465:Cell Movement; D002470:Cell Survival; D002648:Child; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D016952:Legionella pneumophila / Q000187:drug effects; D008089:Listeria monocytogenes / Q000187:drug effects; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D009504:Neutrophils / Q000187:drug effects* / Q000382:microbiology; D010587:Phagocytosis; D013211:Staphylococcus aureus / Q000187:drug effects; D013481:Superoxides / Q000378:metabolism*; D014316:Tritium
D000900:Anti-Bacterial Agents; D018942:Macrolides; D014316:Tritium; D013481:Superoxides; C053853:dirithromycin; D004917:Erythromycin